

Antibiotics

Containing the
Beta-Lactam Structure II

Editors: A. L. Demain and N. A. Solomon



Springer-Verlag
Berlin Heidelberg New York Tokyo

Antibiotics

Containing the Beta-Lactam Structure

Part II

Contributors

P. Actor · M. C. Browning · N. H. Georgopapadakou · J. R. E. Hoover
K. C. Kwan · A. K. Miller · J. D. Rogers · R. B. Sykes · B. M. Tune
J. V. Uri

Editors

A. L. Demain and N. A. Solomon



Springer-Verlag Berlin Heidelberg New York Tokyo 1983

Professor Dr. ARNOLD L. DEMAIN
Ms. NADINE A. SOLOMON
Fermentation Microbiology Laboratory
Department of Nutrition and Food Science
Massachusetts Institute of Technology
Cambridge, MA 02139/USA

With 46 Figures

ISBN 3-540-12131-5 Springer-Verlag Berlin Heidelberg New York Tokyo
ISBN 0-387-12131-5 Springer-Verlag New York Heidelberg Berlin Tokyo

Library of Congress Cataloging in Publication Data. Main entry under title: Antibiotics containing the beta-lactam structure. (Handbook of experimental pharmacology; v. 67, pt. 1-) Includes index. 1. Antibiotics-Synthesis. 2. Beta-lactamases. 3. Fungi-Genetics. [DNLM: 1. Antibiotics-Pharmacodynamics. 2. Beta-lactamases-Pharmacodynamics. W1 HA51L v. 67/QV 350 A62935] QP905.H3 vol. 67, pt. 1, etc. 615'.1s 82-19689 [QD375] [547.7'6]

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically those of translation, reprinting, re-use of illustrations, broadcasting, reproduction by photocopying machine or similar means, and storage in data banks. Under § 54 of the German Copyright Law where copies are made for other than private use, a fee is payable to "Verwertungsgesellschaft Wort", Munich.

© by Springer-Verlag Berlin Heidelberg 1983

Printed in Germany.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Product Liability: The publisher can give no guarantee for information about drug dosage and application thereof contained in this book. In every individual case the respective user must check its accuracy by consulting other pharmaceutical literature.

Typesetting, printing and bookbinding: Brühlsche Universitätsdruckerei, Giessen
2122/3130-543210

Handbook of Experimental Pharmacology

Continuation of Handbuch der experimentellen Pharmakologie

Vol. 67/II



Editorial Board

G. V. R. Born, London · A. Farah, Rensselaer, New York
H. Herken, Berlin · A. D. Welch, Memphis, Tennessee

Advisory Board

S. Ebashi · E. G. Erdös · V. Erspamer · U. S. von Euler · W. S. Feldberg
G. B. Koelle · M. Rocha e Silva · J. R. Vane · P. G. Waser

Preface

It is quite amazing that the oldest group of medically useful antibiotics, the β -lactams, are still providing basic microbiologists, biochemists, and clinicians with surprises over 50 years after Fleming's discovery of penicillin production by *Penicillium*. By the end of the 1950s, the future of the penicillins seemed doubtful as resistant strains of *Staphylococcus aureus* began to increase in hospital populations. However, the development of semisynthetic penicillins provided new structures with resistance to penicillinase and with broad-spectrum activity. In the 1960s, the discovery of cephalosporin C production by *Cephalosporium* and its conversion to valuable broad-spectrum antibiotics by semisynthetic means excited the world of chemotherapy. In the early 1970s, the 40-year-old notion that β -lactams were produced only by fungi was destroyed by the discovery of cephamycin production by *Streptomyces*. Again this basic discovery was exploited by the development of the semisynthetic cefoxitin, which has even broader activity than earlier β -lactams. Later in the 1970s came the discoveries of nocardicins from *Nocardia*, clavulanic acid from *Streptomyces*, and the carbapenems from *Streptomyces*. Now in the 1980s we learn that β -lactams are produced even by unicellular bacteria and that semisynthetic derivatives of these monobactams may find their way into medicine. Indeed, the future of the prolific β -lactam family seems brighter with each passing decade.

Considering the level of excitement in this area, we felt that this would be the right time for the leaders in the field to survey past and present research, development, and clinical applications of β -lactams and prospects for future progress. We were pleasantly surprised that so many busy people agreed to give up their time to contribute to this project. The result is this volume in two parts describing all aspects of β -lactam antibiotics.

Cambridge

ARNOLD L. DEMAIN
NADINE A. SOLOMON

List of Contributors

Dr. P. ACTOR, Smith Kline & French Laboratories, 1500 Spring Garden Street,
P.O. Box 7929, Philadelphia, PA 19101/USA

Dr. M. C. BROWNING, Stanford University School of Medicine, Division of
Nephrology, Department of Pediatrics, Stanford, CA 94305/USA

Dr. N. H. GEORGOPAPADAKOU, The Squibb Institute for Medical Research,
E. R. Squibb & Sons, Inc., P.O. Box 4000, Princeton, NJ 08540/USA

Dr. J. R. E. HOOVER, Chemistry Research, Smith Kline & French Laboratories,
1500 Spring Garden Street, P.O. Box 7929, Philadelphia, PA 19101/USA

Dr. K. C. KWAN, Biopharmaceutics, Merck Institute for Therapeutic Research,
West Point, PA 19486/USA

Dr. A. K. MILLER, 104B Duncan Hill, Westfield, NJ 07090/USA

Dr. J. D. ROGERS, Merck Sharp & Dohme Research Laboratories, West Point,
PA 19486/USA

Dr. R. B. SYKES, The Squibb Institute for Medical Research, E. R. Squibb & Sons,
Inc., P.O. Box 4000, Princeton, NJ 08540/USA

Dr. B. M. TUNE, Stanford University School of Medicine, Division of Nephrology,
Department of Pediatrics, Stanford, CA 94305/USA

Dr. J. V. URI, Clinical Investigation, Smith Kline & French Laboratories, 1500
Spring Garden Street, P.O. Box 7929, Philadelphia, PA 19101/USA

Contents of Companion Volume 67, Part I

CHAPTER 1

History of β -Lactam Antibiotics

E. P. ABRAHAM

CHAPTER 2

Mode of Action of β -Lactam Antibiotics – A Microbiologist's View

A. TOMASZ. With 17 Figures

CHAPTER 3

Strain Improvement and Preservation of β -Lactam-Producing Microorganisms

R. P. ELANDER. With 9 Figures

CHAPTER 4

Genetics of β -Lactam-Producing Fungi

C. BALL. With 4 Figures

CHAPTER 5

Genetics of β -Lactam-Producing Actinomycetes

R. KIRBY. With 4 Figures

CHAPTER 6

Biosynthesis of β -Lactam Antibiotics

A. L. DEMAIN. With 6 Figures

CHAPTER 7

Regulation of Biosynthesis of β -Lactam Antibiotics

J. F. MARTIN and Y. AHARONOWITZ. With 5 Figures

CHAPTER 8

Biochemical Engineering and β -Lactam Antibiotic Production

D.-G. MOU. With 13 Figures

CHAPTER 9

Screening for New β -Lactam Antibiotics

S. B. ZIMMERMAN and E. O. STAPLEY. With 7 Figures

CHAPTER 10

High-Performance Liquid Chromatography of β -Lactam Antibiotics

R. D. MILLER and N. NEUSS. With 18 Figures

CHAPTER 11

Strategy in the Total Synthesis of β -Lactam Antibiotics

B. G. CHRISTENSEN and T. N. SALZMANN

Subject Index

Contents

CHAPTER 12

Bacterial Enzymes Interacting with β -Lactam Antibiotics

N. H. GEORGOPAPADAKOU and R. B. SYKES. With 10 Figures

A. Introduction	1
I. Classification of β -Lactam Antibiotics	3
II. Mode of Action of β -Lactam Antibiotics	4
1. Structure and Synthesis of Peptidoglycan	4
2. The Tipper and Strominger Hypothesis for Penicillin Action	7
III. Classification of Enzymes Interacting with β -Lactam Antibiotics	9
1. Enzymes Acting on Peptidoglycan	9
2. Enzymes Degrading β -Lactam Antibiotics	10
B. Bacterial Proteins Binding β -Lactam Antibiotics	12
I. General	12
II. Penicillin-Binding Proteins in Gram-Negative Bacteria	15
1. <i>Escherichia coli</i>	15
2. Other Enterobacteria	17
3. Pseudomonads	20
4. Other Bacteria	21
III. Penicillin-Binding Proteins in Gram-Positive Bacteria	21
1. Bacilli	21
2. Micrococci	23
3. Streptococci	24
4. Actinomycetes	24
C. Enzymes Inhibited by β -Lactam Antibiotics	25
I. DD-Carboxypeptidases	25
1. DD-Carboxypeptidases in Gram-Negative Bacteria	30
2. DD-Carboxypeptidases in Gram-Positive Bacteria	31
II. Peptidoglycan Transpeptidase	35
D. β -Lactamases	36
I. General	36
II. β -Lactamases in Gram-Positive Bacteria	37
1. Staphylococci	39
2. Bacilli	40
3. Streptomycetes	43
4. Other Actinomycetes	43

III. β -Lactamases in Gram-Negative Bacteria	44
1. Anaerobic	45
2. Aerobic	45
E. Interaction with the β -Lactam Nucleus	54
I. Components of the Interaction	54
1. Kinetic Parameters	54
2. Conformational Changes	56
3. Nature of the Covalent Complex	56
4. Nature of Release Products	57
II. <i>Streptomyces</i> R61 DD-Carboxypeptidase	58
III. β -Lactamases and β -Lactam Inhibitors	59
1. Clavulanic Acid	59
2. Penicillin Sulfones	60
3. Halopenicillanic Acids	61
4. Carbapenems	61
F. Concluding Remarks	62
References	63

CHAPTER 13

In Vitro and In Vivo Laboratory Evaluation of β -Lactam Antibiotics

A. K. MILLER

A. Historical	79
I. Penicillins	79
II. Cephalosporins	82
III. Cephamycins (7- α -Methoxy Cephalosporins)	83
IV. β -Lactams of Novel Structure	84
B. β -Lactam Laboratory Evaluation Procedures	85
I. Introduction	85
II. In Vitro Test Procedures	86
1. Spectrum of Activity and Sensitivity Tests	86
2. Speed of Action Test	89
3. Susceptibility Disc Test	89
4. Interaction and Synergy Tests	90
5. Effect on Morphology	91
6. Procedures Using Anaerobes	92
7. Factors Influencing In Vitro Tests	93
8. Enzymes and Resistance to β -Lactam Antibiotics	93
9. Automation and Miniaturization	94
10. In Vitro Models to Simulate In Vivo Conditions	94
III. In Vivo Test Procedures	95
1. Mouse Protection Test	95
2. Specialized Test Procedures	98
3. Tests Using Anaerobes	101
IV. In Vitro-In Vivo Relationships	101
C. Representative β -Lactam Agents	102
References	107

CHAPTER 14

 β -Lactam Antibiotics: Structure–Activity Relationships. J. R. E. HOOVER

With 8 Figures

A. Introduction: Scope	119
I. Structure	119
II. Activity	121
B. Clinically Useful Penicillins	122
I. Natural, Biosynthetic, and Related Penicillins	125
II. Penicillinase-Resistant Penicillins	127
III. Broad-Spectrum Penicillins	131
1. α -Aminopenicillins	132
2. α -Carboxy and α -Sulfopenicillins	134
3. Acylampicillins	136
4. 6-Acylamino Alternatives: Quaternary Heterocyclic Aminopenicillanic Acids and 6-Amidinopenicillanic Acids	139
5. A 6 α -Methoxy Penicillin (Temocillin)	142
C. Clinically Useful Cephalosporins	144
I. Basic Structure–Activity Relationships	144
II. β -Lactamase-Sensitive Cephalosporins	149
1. 7 β -Acylamino Group Modifications	149
2. Metabolic Stability	153
3. 3-Substituent Modifications	154
III. Cephalosporins with Special Pharmacokinetic Properties	160
1. Cephalosporins with High and Prolonged Serum Levels	161
2. Cephalosporins Absorbed Orally	164
IV. β -Lactamase-Resistant Cephalosporins	168
1. Cephalosporins with Moderate β -Lactamase Resistance	168
2. Cephamecins	172
3. Cephalosporins with Significant β -Lactamase Resistance	174
V. Oxacephalosporins	180
D. Nonclassic β -Lactams	185
I. Penems and Carbapenems	185
1. Carbapenems: Thienamycins, Olivanic Acids, and Related Structures	186
2. Penems	197
3. Oxapenems	202
II. Monocyclic β -Lactams	203
1. Nocardicins	203
2. Monobactams	206
III. β -Lactamase Inhibitors	212
1. Penicillins and Cephalosporins as Inhibitors	212
2. Progressive β -Lactamase Inhibitors	214
E. Other Structure–Activity Relationships	226
References	226

CHAPTER 15

Pharmacokinetics of β -Lactam Antibiotics. K. C. KWAN and J. D. ROGERS

With 28 Figures

A. Introduction	247
B. Penicillins	247
I. Benzylpenicillin (Penicillin G)	248
II. Phenoxymethylpenicillins	251
1. Phenoxymethylpenicillin (Penicillin V)	251
2. Pheneticillin	253
3. Propicillin	253
4. Phenbenicillin	254
III. Clometocillin	254
IV. Methicillin	255
V. Ancillin	256
VI. Nafcillin	257
VII. Isoxazolylpenicillins	258
1. Oxacillin	258
2. Cloxacillin	260
3. Dicloxacillin	261
4. Flucloxacillin	262
VIII. Ampicillin	263
1. Hetacillin	265
2. Pivampicillin	266
3. Bacampicillin	267
4. Talampicillin	267
5. Metampicillin	268
6. Methoxymethyl Ester of Hetacillin	268
IX. Amoxicillin	268
X. Azidocillin	269
XI. Epicillin	270
XII. Cyclacillin	271
XIII. Carbenicillin	271
1. Carindacillin	273
2. Carfecillin	273
XIV. Ticarcillin	273
XV. Sulbenicillin	274
XVI. Ureidopenicillins	274
1. Azlocillin	275
2. Mezlocillin	276
3. Piperacillin	277
4. Bay k 4999	277
5. BL-P1654	277
C. Cephalosporins	278
I. Cephalosporanic Acids	278
1. Cephalothin	278
2. Cephapirin	283

3. Cefotaxime	284
4. Cephaloglycine	287
5. Cephacetrile	289
II. Desacetoxyccephalosporanic Acids	291
1. Cephalixin	291
2. Cephhradine	295
3. Cefadroxil	298
4. FR-10612	299
5. HR-580	299
6. RMI 19,592	300
III. 3-(5-Methyl-1,3,4-thiadiazol-2-ylthiomethyl)ceph-3-em-4-oic Acids	300
1. Cefazolin	300
2. Cephانون	304
3. Cefazedone	305
4. Ceftezole	306
IV. 3-(1-Pyridylmethyl)-ceph-3-em-4-oic Acids	307
1. Cephaloridine	307
2. Cefsulodin (CGP 7174/E, SCE-129)	310
3. GR20263	311
V. 3-[[1-(1-Methyl-1H-tetrazol-5-yl)thio]methyl]-ceph-3-em-4-oic Acids	311
1. Cefamandole Nafate	311
2. Ceforanide	315
3. Cefazaflur	316
4. Cefoperazone	317
5. Cefonicid (SKF-75073)	318
VI. Derivatives of 3-Desacetoxymethylcephalosporanic Acid	319
1. Cefroxadine	319
2. Cefaclor	320
3. Cefatrizine	321
VII. Cefuroxime	322
VIII. Ceftizoxime	325
IX. Ro 13-9904	325
X. Cephamycins	326
1. Cefoxitin	326
2. Cefmetazole (CS-1170)	329
D. Other β -Lactam Antibiotics	330
I. Moxalactam (LY 127935)	330
II. Clavulanic Acid	331
III. Mecillinam	332
References	333

CHAPTER 16

Toxicology of β -Lactam Antibiotics. M. C. BROWNING and B. M. TUNE

A. Introduction	371
B. Local Reactions to Parenteral Administration	371

C. Gastrointestinal Side Effects	371
I. Nonspecific Diarrhea	372
II. Pseudomembranous Colitis	372
III. Ischemic Colitis	373
D. Immunologically Mediated Toxicity	373
I. Human Toxicity	373
II. Sensitization Process	373
E. Immune Hemolytic Anemia	375
F. Neutropenia	376
G. Disorders of Hemostasis	377
I. Thrombosthenia	377
II. Plasma Factor Coagulopathy	378
III. Thrombocytopenia	378
H. Interstitial Nephritis and Cystitis	378
I. Clinical Picture	379
II. Immunofluorescence	379
III. Cystitis	380
I. Nephrotoxicity	380
I. Human Toxicity	380
II. Cellular Mechanisms	381
1. Uptake	381
2. Efflux: Cephaloridine	381
3. Reactivity or Receptor Affinity: Cephaloglycin	382
III. Less Toxic Cephalosporins	382
1. Additive Aminoglycoside-Cephalosporin Toxicity	383
2. Effects of Ureteral Obstruction	384
IV. Molecular Basis of Toxicity	384
1. Metabolite Hypothesis	384
2. Mitochondrial Respiratory Toxicity	385
J. Hepatic Toxicity	385
K. Neurotoxicity	386
I. Human Toxicity	386
II. Animal Toxicity	386
III. Mechanism	387
1. Effects on Gamma-Aminobutyric Acid (GABA)-Mediated Transmission	387
2. Effects on Chloride Conductance	387
3. Effects on the Sodium-Potassium Exchange Pump	388
IV. Structure-Activity Relationships	388
V. Regulation of Penicillin Concentration in the Central Nervous System	389
VI. Nonspecific Neurotoxic Reactions	389
L. Disulfiram-Like Reactions	389
M. Newer β -Lactams	390
References	390

CHAPTER 17

Therapeutic Application of β -Lactam Antibiotics. J. V. URI and P. ACTOR

A. Introduction	399
B. Penicillins in the Therapy of Human Infections	400
I. The Penams: The Biosynthetic or Natural Penicillins	406
1. Penicillin G (Benzylpenicillin)	406
2. Penicillin V and the Acid-Stable Phenoxypenicillins	409
II. The Penicillinase-Resistant Penicillins	410
1. Methicillin	410
2. Nafcillin	412
3. Isoxazolyl Penicillins	413
III. The Broad-Spectrum Aminopenicillins	414
1. Ampicillin	415
2. Esters of Ampicillin	417
3. Amoxicillin	418
4. Epicillin and Cyclacillin	419
IV. The Antipseudomonal Penicillins	419
1. Carbenicillin	420
2. Ticarcillin	422
V. The Amidinopenicillanic Acids – Amdinocillin	425
VI. The Atypical β -Lactams	426
1. The Monocyclic β -Lactams	426
2. The Oxapenams	428
3. The Carbapenems	428
4. The Penems	429
C. Cephalosporins in the Therapy of Human Infections.	429
I. Cephalothin	433
II. Cephaloridine	433
III. Cefazolin	434
IV. Cefamandole	435
V. Cefoxitin	436
VI. Cefmetazole	436
VII. Cefuroxime	437
VIII. Ceforanide	437
IX. Cefonicid	438
X. Third-Generation Cephalosporins	438
1. Cefotaxime	439
2. Ceftizoxime	441
3. Moxalactam	441
4. Cefoperazone	442
5. Ceftriaxon	443
6. Cefmenoxime	443
7. Ceftazidime	443
8. Cefotiam	444
9. Cefsulodin	444

XI. The Oral Cephalosporins	445
1. Cephalexin	445
2. Cephradine	446
3. Cefatrizine	446
4. Cefaclor	446
5. Cefroxadine, Cefadroxil, and Cephaloglycin	447
D. Antibacterial Chemoprophylaxis with the β -Lactam Antibiotics	447
I. Prophylactic Uses in Medicine	448
II. Prophylactic Uses in Surgery	451
E. Use of β -Lactam Antibiotics in Dental Medicine	453
F. Use of β -Lactam Antibiotics in Veterinary Practice	455
References	458
Subject Index	471

Bacterial Enzymes Interacting with β -Lactam Antibiotics

N. H. GEORGOPAPADAKOU and R. B. SYKES

A. Introduction

Development of β -lactam antibiotics over the past 40 years represents an unparalleled effort in the history of antimicrobial chemotherapy. The continual emergence of new compounds, natural, semisynthetic, and synthetic, is a tribute to the research programs being carried out around the world. Alongside the intensive search for new and improved β -lactam antibiotics has been the study of enzymes that interact with these molecules.

Early studies were conducted on the penicillin-hydrolyzing enzymes (β -lactamases), initially detected by ABRAHAM and CHAIN in 1940. These enzymes, responsible for the penicillin resistance among staphylococci in the 1940s and 1950s, have since proved to be a major source of resistance in gram-negative organisms. Throughout the 40-year history of β -lactam antibiotics, β -lactamases have continually asserted their presence. They have proved to be extremely important as antibiotic resistance agents and, as such, have given impetus to antibiotic development programs. Other enzymes implicated in the hydrolysis of penicillins and cephalosporins are the acylases and esterases. Although of little importance as antibiotic-resistance agents, these enzymes have played a significant part in the production of semisynthetic β -lactam antibiotics.

The second group of enzymes interacting with β -lactam antibiotics have the opposite physiological role to the β -lactamases, i.e., they are inactivated by these compounds. The effects of penicillin on cell-wall structure and morphology were shown soon after its introduction, and by the late 1950s penicillin was reported to be a specific inhibitor of bacterial cell-wall synthesis. During the following decade, the structure of the bacterial cell wall and the mechanism of its synthesis were elucidated. Following on from these studies in the 1970s came the isolation and identification of the two types of bacterial enzymes sensitive to penicillin, peptidoglycan transpeptidase and DD-carboxypeptidase.

Abbreviations

6-APA, 6-Aminopenicillanic acid; pCMB, p-chloromercuribenzoate; Diac-L-Lys-D-Ala-D-Ala, α,ϵ -diacetyl-L-lysyl-D-alanyl-D-alanine; Diac-L-Lys-D-Ala-D-Lac, α,ϵ -diacetyl-L-lysyl-D-alanyl-D-lactate; DFP, diisopropylfluorophosphate; DTNB, 5,5'-dithiobis (2-nitrobenzoic acid); pI, isoelectric point; MSF, methanesulfonyl fluoride; MIC, minimum inhibitory concentration; NEM, N-ethylmaleimide; PBP, penicillin-binding protein; PSE, penicillin-sensitive enzyme; SDS, sodium dodecylsulfate; UDP-MurNac-L-Ala-D-Glu-meso-Dap-D-Ala-D-Ala, UDP-N-acetylmuramyl-L-alanyl- γ -D-glutamyl-meso-2,6-diaminopimelyl-D-alanyl-D-alanine